September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Targeted Delivery of YSA-Functionalized PLGA Nanoparticles to Endothelial Cells
Author Affiliations & Notes
  • Arun K Upadhyay
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, Colorado, United States
  • Todd Carpenter
    Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, Colorado, United States
  • Eva Grayck
    Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, Colorado, United States
  • Uday B Kompella
    Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, Colorado, United States
  • Footnotes
    Commercial Relationships   Arun Upadhyay, None; Todd Carpenter, None; Eva Grayck, None; Uday Kompella, None
  • Footnotes
    Support  NIH grant R01HL119533
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3994. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arun K Upadhyay, Todd Carpenter, Eva Grayck, Uday B Kompella; Targeted Delivery of YSA-Functionalized PLGA Nanoparticles to Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3994.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : YSA is a peptide that binds to EphA2 receptors on vascular endothelial cells. The purpose of this study was to determine whether YSA functionalization enhances nanoparticle delivery into Human Umbilical Vein Endothelial Cells (HUVEC).

Methods : Nile red loaded poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared using double emulsion and solvent evaporation method. Nanoparticles were chemically conjugated to YSA peptide and a scrambled YSA peptide through 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDAC) and N-hydroxysuccinimide (NHS) activation of carboxyl group present on acid terminated PLGA polymer. Nile red in nanoparticles was quantified using fluorescence spectroscopy following dichloromethane extraction. Nile red content was estimated by measuring fluorescence at excitation and emission wavelengths of 560 and 640 nm, respectively. NPs were dispersed in water and size and zeta potential were measured using Malvern Nano-ZS instrument. In vitro uptake of functionalized nanoparticles was determined in HUVEC cells. Briefly, 10,000 cells were seeded in 96-well plate and after 24 hour of incubation in serum containing medium, cells were washed with PBS and treated with 200 μl of 0.5 mg/ml nanoparticles in serum free medium for 3 h. At the end of the incubation period, the medium was removed, cell monolayer was washed 2 times each with physiological PBS (7.4) and acidic PBS (pH 5.2), and the cells were lysed using RIPA buffer. Nile red from particles in the lysate was extracted and quantified.

Results : Control and functionalized Nile red loaded PLGA nanoparticles had a mean diameter of in the range of 250-300 nm and a negative zeta-potential. HUVEC cells showed ~150 % higher uptake of YSA-functionalized Nile red loaded PLGA nanoparticles, when compared to control nanoparticles. Scrambled YSA-functionalized nanoparticles showed about 90 % uptake relative to control NPs. The absolute bioavailability of control NPs was 6.7%.

Conclusions : Functionalization of Nile red loaded PLGA NPs with YSA peptide enhances cellular delivery of nanoparticles in HUVEC cells. EphA2 receptor is a potential target for accumulating nanoparticles in vascular endothelium.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×